Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants

Radiographics

Volumn 19, Issue 1, 1999, Pages 61-77

  Shreve, Paul D ^a,c   Anzai, Yoshimi ^b   Wahl, Richard L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Emission CT (ECT), **.121632; Fluorine; Neoplasms, diagnosis, **.30; Neoplasms, emission CT (ECT), **.12163, **.30

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; HUMAN; LABORATORY DIAGNOSIS; METHODOLOGY; NEOPLASM; REVIEW; SCINTISCANNING;

DIAGNOSIS, DIFFERENTIAL; FALSE POSITIVE REACTIONS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032616268     PISSN: 02715333     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiographics.19.1.g99ja0761     Document Type: Article

References (39)

1. Rigo P, Paulus P, Kaschten BJ, et al. Oncologic applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23:1641-1674.
2. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994; 35:1308-1312.
3. Jones SC, Alavi A, Christman D, Montanez I, Wolf AP, Reivich M. The radiation dosimetry of 2-[F-18] fluoro-2-deoxy-D-glucose in man. J Nucl Med 1982; 23:613-617.
4. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer: a PET study. J Nucl Med 1993; 34:1-6.
5. 18F] fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin. J Comput Assist Tomogr 1993; 17:115-123.
6. Torizuka T, Fisher SJ, Wahl RL. Insulin-induced hypoglycemia decreases uptake of 2-[F-18]fluoro-2-deoxy-D-glucose into experimental mammary carcinoma. Radiology 1997; 203:169-172.
7. Dahlbom M, Hoffman EJ, Hoh CK, et al. Whole-body positron emission tomography: methods and performance characteristics. J Nucl Med 1992; 33:1191-1199.
8. Zasadny KR, Kison PV, Quint LE, Wahl RL. Untreated lung cancer: quantification of systematic distortion of tumor size and shape on non-attenuation-corrected 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET scans. Radiology 1996; 201:873-876.
9. Bailey DL. Transmission scanning in emission tomography. Eur J Nucl Med 1998; 25:774-787.
10. Bengel FM, Ziegler SI, Avril N, Weber W, Laubenbacher C, Schwaiger M. Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images. Eur J Nucl Med 1997; 24:1091-1098.
11. Imran MB, Kubota K, Yamada S, et al. Lesion-to-background ratio in non-attenuation-corrected whole-body FDG PET images. J Nucl Med 1998; 39:1219-1223.
12. Vesselle HJ, Miraldi FD. FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. RadioGraphics 1998; 18:805-823.
13. Bedigian MP, Benard F, Smith RJ, Karp JS, Alavi A. Whole-body positron emission tomography for oncology imaging using singles transmission scanning with segmentation and ordered subsets-expectation maximization (OS-EM) reconstruction. Eur J Nucl Med 1998; 25:659-661.
14. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994; 35:1308-1312.
15. Torizuka T, Zasadny KR, Recker B, Wahl RL. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology 1998; 207:767-774.
16. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189:847-850.
17. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36:1836-1839.
18. Stollfuss JC, Glatting G, Friess H, Kocher F, Beger HG, Reske SN. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 1995; 195:339-344.
19. Lowe VJ, Fletcher JW, Gobar L. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998; 16:1075-1084.
20. Brigid GA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. AJR 1997; 169: 1675-1680.
21. Meyer MA. Diffusely increased colonic F-18 FDG uptake in acute enterocolitis. Clin Nucl Med 1995; 20: 434-435.
22. Miraldi F, Vesselle H, Faulhaber PF, Adler LP, Leisure GP. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med 1998; 23:3-7.
23. Conti PS, Durski JM, Singer PA, Austin T. Incidence of thyroid gland uptake of F-18 FDG in cancer patients (abstr). Radiology 1997; 205(P):220.
24. Jabour BA, Choi Y, Holi CK, et al. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology 1993; 186:27-35.
25. Barrington SF, Maisey MN. Skeletal muscle uptake of fluorine-18-FDG: effect on oral diazepam. J Nucl Med 1996; 37:1127-1129.
26. Kostakoglu L, Wong JCH, Barrington SF, Cronin BF, Dynes AM, Maisey MN. Speech-related visualization of laryngeal muscles with fiuorine-18-FDG. J Nucl Med 1996; 37:1771-1773.
27. Mossberg KA, Mommessin JI, Taegtmeyer H. Skeletal muscle glucose uptake during short-term contractile activity in vivo: effect of prior contractions. Metabolism 1993; 42:1609-1616.
28. Cook GJR, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996; 26:308-314.
29. Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA, von Schulthess GK. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996; 37:441-446.
30. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heat muscle. Annu Rev Physiol 1974; 36: 413-459.
31. Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Pre-clinical and clinical studies of bone marrow uptake of fluorine-18-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998; 16:173-180.
32. 18F]fluoro-D-glucose in the normal testis: retrospective PET study and animal experiment. Ann Nucl Med 1997; 11:195-199.
33. Meyer M, Gast T, Raja S, Hubner K. Increased F-18 FDG accumulation in an acute fracture. Clin Nucl Med 1994; 19:13-14.
34. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35: 1647-1649.
35. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996; 23: 1409-1415.
36. Tahara T, Ichiya Y, Kuwabara U, et al. High [18F]-fluorodeoxyglucose uptake in abdominal abscesses: a PET study. J Comput Assist Tomogr 1989; 13:829-831.
37. Yasuda S, Shohtsu A, Ide M, Takagi S, Kijima H, Horiuchi M. Elevated F-18 FDG uptake in plasmacyte-rich chronic maxillary sinusitis. Clin Nucl Med 1998; 23:176-178.
38. Shreve PD. Focal flourine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 1998; 25:259-264.
39. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 1995; 36:771-777.